PL1638529T3 - Kompozycja doustna o przedłużonym uwalnianiu - Google Patents

Kompozycja doustna o przedłużonym uwalnianiu

Info

Publication number
PL1638529T3
PL1638529T3 PL04776663T PL04776663T PL1638529T3 PL 1638529 T3 PL1638529 T3 PL 1638529T3 PL 04776663 T PL04776663 T PL 04776663T PL 04776663 T PL04776663 T PL 04776663T PL 1638529 T3 PL1638529 T3 PL 1638529T3
Authority
PL
Poland
Prior art keywords
release composition
oral extended
oral
extended
release
Prior art date
Application number
PL04776663T
Other languages
English (en)
Inventor
Boyong Li
Avinash Nangia
Monte Browder
Original Assignee
Andrx Pharmaceuticals, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals, Llc. filed Critical Andrx Pharmaceuticals, Llc.
Publication of PL1638529T3 publication Critical patent/PL1638529T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04776663T 2003-06-16 2004-06-16 Kompozycja doustna o przedłużonym uwalnianiu PL1638529T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47891503P 2003-06-16 2003-06-16

Publications (1)

Publication Number Publication Date
PL1638529T3 true PL1638529T3 (pl) 2017-03-31

Family

ID=33539127

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04776663T PL1638529T3 (pl) 2003-06-16 2004-06-16 Kompozycja doustna o przedłużonym uwalnianiu

Country Status (6)

Country Link
US (2) US7476403B2 (pl)
EP (3) EP2535042A1 (pl)
AU (1) AU2004249211A1 (pl)
CA (3) CA2675724C (pl)
PL (1) PL1638529T3 (pl)
WO (1) WO2004112711A2 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
CA2675724C (en) * 2003-06-16 2012-12-04 Andrx Pharmaceuticals, Llc Oral extended-release composition
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) * 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
AU2005235237A1 (en) * 2004-03-24 2005-11-03 Lupin Limited Clarithromycin extended release formulation
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
RU2401125C2 (ru) * 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ стабилизации лекарственного средства против деменции
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
WO2007123883A2 (en) * 2006-04-17 2007-11-01 Actavis Group Ptc Ehf Oral dosage formulations and methods of preparing the same
US20070243245A1 (en) * 2006-04-17 2007-10-18 Actavis Group Ptc Hf Oral Dosage Formulations, Methods of Preparing the Same, and Methods of Reducing Food Effects on Drug Release
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CN101439025B (zh) * 2008-12-31 2011-05-11 江苏大学 一种水飞蓟素高效长效制剂及其制法
CN101444503B (zh) * 2008-12-31 2011-02-02 江苏大学 一种水飞蓟宾高效长效制剂及其制法
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
JP2013501810A (ja) 2009-08-12 2013-01-17 ヴァリーント インターナショナル（バルバドス）エスアールエル 医薬組成物
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2014047167A1 (en) 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
CA2930744A1 (en) 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
IL288712B2 (en) 2015-03-06 2024-01-01 Auspex Pharmaceuticals Inc Methods for treating abnormal movement disorders
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US4064230A (en) * 1966-04-25 1977-12-20 Schmid Laboratories, Inc. Polyenic macrolide compositions
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS60163823A (ja) 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
ATE66143T1 (de) * 1985-01-11 1991-08-15 Abbott Lab Feste zubereitung mit langsamer freisetzung.
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4808411A (en) 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
KR0168715B1 (ko) 1992-11-30 1999-01-15 밋첼 아이. 커시너 맛을 차단하는 약제학적 조성물
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
MX9603480A (es) 1994-02-16 1997-12-31 Abbott Lab Procedimiento para preparar formulaciones farmaceuticas en particulas finas.
RU2130311C1 (ru) * 1994-05-06 1999-05-20 Пфайзер Инк. Лекарственные формы азитромицина с контролируемым высвобождением
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
JP2000511063A (ja) 1996-07-05 2000-08-29 バイオティカ テクノロジー リミティド ポリケチド類及びそれらの合成
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
SI20108B (en) * 1997-06-11 2001-12-31 Abbott Lab A controlled release formulation for poorly soluble basic drugs
EP1003476B1 (en) * 1997-08-11 2004-12-22 ALZA Corporation Prolonged release active agent dosage form adapted for gastric retention
KR100505464B1 (ko) * 1998-03-26 2005-08-04 후지사와 야꾸힝 고교 가부시키가이샤 서방성 제제
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
CZ300551B6 (cs) * 1999-03-31 2009-06-17 Janssen Pharmaceutica N. V. Predželatinovaný škrob v rízene se uvolnující formulaci
IL149421A0 (en) 1999-11-02 2002-11-10 Depomed Inc Pharmaceutical compositions containing fed mode inducing agents
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6642276B2 (en) 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
AU2003245504A1 (en) 2002-06-14 2003-12-31 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2675724C (en) * 2003-06-16 2012-12-04 Andrx Pharmaceuticals, Llc Oral extended-release composition
AU2005235237A1 (en) * 2004-03-24 2005-11-03 Lupin Limited Clarithromycin extended release formulation

Also Published As

Publication number Publication date
US20050064034A1 (en) 2005-03-24
EP2529730A1 (en) 2012-12-05
CA2673334C (en) 2013-11-12
WO2004112711A2 (en) 2004-12-29
CA2529746A1 (en) 2004-12-29
AU2004249211A1 (en) 2004-12-29
CA2529746C (en) 2010-08-03
CA2673334A1 (en) 2004-12-29
CA2675724C (en) 2012-12-04
EP2535042A1 (en) 2012-12-19
EP1638529B1 (en) 2016-08-10
US20090124563A1 (en) 2009-05-14
EP1638529A4 (en) 2010-01-06
US8628797B2 (en) 2014-01-14
WO2004112711A3 (en) 2005-05-19
US7476403B2 (en) 2009-01-13
CA2675724A1 (en) 2004-12-29
EP1638529A2 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
EP1638529A4 (en) ORAL COMPOSITION WITH PROLONGED RELEASE
GB0305941D0 (en) Composition
PL365518A1 (pl) Kompozycja doustna
GB0302738D0 (en) Composition
GB0324918D0 (en) Composition
HK1093896A1 (en) Medicinal composition
AU2003252683A8 (en) Composition for oral use
GB0324897D0 (en) Composition
HK1087034A1 (en) Actacid composition
GB0322033D0 (en) Composition
GB0325383D0 (en) Oral formulations
MY145151A (en) Composition
EP1600445A4 (en) CURATIVE PREPARATION
PL377147A1 (pl) Doustna kompozycja
IL173743A0 (en) Oral itrazole compositions
GB0309317D0 (en) Composition
GB0306312D0 (en) Composition
GB0324295D0 (en) Composition
GB0326815D0 (en) Composition
GB0301869D0 (en) Composition
GB2390303B (en) Oral compositions
GB0222651D0 (en) Dental compositions
GB0323203D0 (en) Composition II
GB0324168D0 (en) Composition II
GB0301669D0 (en) Composition